Such structural diversity is considered to be an obstacle for vaccine and therapeutic development (He et al., 2020). Neutralizing antibodies (nAbs) are known to target different steps of the viral infection cascade, such as blocking virion-receptor interactions, interfering with dynamic transitions ...